IMMUNOSUPPRESSIVE COMPOUNDS AND COMPOSITIONS Russian patent published in 2010 - IPC C07C251/50 C07D205/04 C07D213/55 C07D211/34 C07D307/54 C07D333/24 C07D217/18 C07C251/60 A61K31/192 A61K31/197 A61K31/341 A61K31/397 A61K31/452 A61K31/381 A61K31/401 A61K31/4418 A61K31/472 A61P25/28 A61P37/06 

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds of formula Ia and their pharmaceutically acceptable salts, hydrates, solvates, esters and amides. In formula Ia , A is specified from -C(O)OR₅ where R₅ represents hydrogen; W represents C_1-3alkylene; Y is specified from phenyl and 5-6-member heteroaryl containing one heteroatom specified from N, S, O; where any phenyl or heteroaryl Y can be optionally substituted with 1 to 3 radicals specified from halogen, C_1-6alkyl, C_1-6alkoxygroup, halogen-substituted C_1-6alkyl and halogen-substituted C_1-6alkoxygroup; Z is specified from: where left and right asterisks Z specify an attachment point between -C(R₃)(R₄)- and A of formula la; R₆ is specified from hydrogen and C_1-6alkyl; or R₆ can be attached to carbon atom in Y to form a 5-7-member ring; R₁ is specified from phenyl and 5-member heteroaryl containing one heteroatom specified from S, O; where any phenyl or heteroaryl R₁ is substituted with a radical specified from phenylC_0-4alkyl, heteroarylC_0-4alkyl where heteroaryl represents 5-6-member heteroary containing one heteroatom specified from N, S, O, C_3-8cycloalkylC_0-4alkyl, C_3-8heterocycloalkylC_0-4alkyl which contains nitrogen atom as heteroatom, or C_1-6alkyl; where any phenyl, heteroaryl, cycloalkyl or heterocycloalkyl group R₁ can be optionally substituted with 1 to 3 radicals specified from halogen, C_1-6alkyl, C_1-6alkoxygroup, halogen-substituted C_1-6alkyl group and halogen-substituted C_1-6alkoxygroup; R₂ represents C_1-6alkyl group; R₃ and R₄ represent hydrogen.

EFFECT: preparation of the pharmaceutical composition exhibiting EDG/S1P receptor modulating properties, containing therapeutically effective amount of the compound under the invention, development of a method of treating the disease mediated by EDG/S1P receptor activity, application of the compounds for preparing a drug for prevention or treatment of the disease mediated by EDG/S1P receptor activity.

16 cl, 1 tbl, 86 ex